NNRTI choice: Has 2NN changed our practice?

AIDS Reader

Volumn 13, Issue 7, 2003, Pages 325-328

  Moyle, Graeme J ^a  

^a NONE

Author keywords

Efavirenz; HIV AIDS; Nevirapine; NNRTIs

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR;

CENTRAL NERVOUS SYSTEM DISEASE; DRUG EFFICACY; HEPATOBILIARY DISEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MENTAL DISEASE; RASH; REVIEW; TREATMENT OUTCOME; VIRUS LOAD;

EID: 0038037025     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. van Leth F, Hassink E, Phanuphak P, et al. Results of the 2NN study: a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston. Abstract 176.
2. Keiser P, Nassar N, White C, et al. Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naive patients: a cohort study. HIV Clin Trials. 2002;3:296-303.
3. Matthews GV, Sabin CA, Mandalia S, et al. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS. 2002;16:53-61.
4. Cozzi-Lepri A, Phillips AN, d'Arminio Monforte A, et al. Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (ICoNA) study. J Infect Dis. 2002;185:1062-1069.
5. Phillips AN, Pradier C, Lazzarin A, et al. Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. AIDS. 2001;15:2385-2395.
6. Moyle GJ, Wilkins E, Leen C, et al. Salvage therapy with abacavir plus efavirenz or nevirapine in HIV-1-infected persons with previous nucleoside analogue and protease inhibitor use. AIDS, 2000;14:1453-1454.
7. Montaner JSG. The 2NN Study: nevirapine-versus evfavirenz-based HAART regimens. In: Selected highlights from the 10th Conference on Antiretroviruses and Opportunistic Infections. Available at: http://www.hivandhepatitis.com/2003icr/10thretro/main.html. Accessed June 5, 2003.
8. Hicks C. The 2NN Study: clinical trials in treatment naive and experienced patients. In: Selected highlights from the 10th Conference on Antiretroviruses and Opportunistic Infections. Available at: http://www.hivandhepatitis.com/2003icr/10thretro/main.html. Accessed June 5, 2003.
9. Moyle GJ. Truth, lies, and statistical tests. AIDS Reader. 2003;13:117-118, 123-126.
10. US DHHS Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. February 4, 2002. Available at: http://www.aidsinfo.nih.gov/guidelines/default_dbz.asp?id=50. Accessed June 5, 2003.
11. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA panel. JAMA. 2002;288:222-235.
12. Friis-Møller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17:1179-1193.
13. Reiss P. New insights in the clinical management of HIV-1 associated metabolic complications - putting guidelines into perspective. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections, February 10-14, 2003; Boston. Abstract 163.
14. Staszewski S, Gallant JE, Posniak AL, et al. Efficacy and safety of tenofovir DF (TDF) versus stavudine (d4T) when used in combination with lamivudine and efavirenz in antiretroviral naive patients: 96-week preliminary interim results. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston. Abstract 564b.
15. Arribas JR, Pulido F, Miro JM, et al. High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/microl and opportunistic diseases: the EfaVIP Study (Efavirenz in Very Immunosuppressed Patients). AIDS. 2002;16:1554-1556.
16. Pollard R and the 1090 Team. Factors predictive of durable HIV suppression in randomized double-blind trial with nevirapine (NVP), zidovudine (ZDV), and lamivudine (3TC) in treatment-naive (ARV-n) patients with advanced AIDS. Poster. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco. Abstract 517.